Document:

<PAGE>
                                                                   EXHIBIT 10.12

                          TRUBION PHARMACEUTICALS, INC.

                         COMMON STOCK PURCHASE AGREEMENT

      This Common Stock Purchase Agreement (this "Agreement") is made as of
December 19, 2005 by and between Trubion Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), and Wyeth, a Delaware corporation (the
"Purchaser").

                                    RECITALS

      A. The Purchaser and the Company are entering into a collaboration
agreement of even date herewith (the "Collaboration Agreement");

      B. In connection with the Collaboration Agreement, Purchaser desires to
purchase from the Company shares of its Common Stock (the "Common Stock"),
concurrently with and conditioned upon the closing of the Company's initial
public offering, upon the terms and conditions set forth herein;

      C. The Company and the Purchaser wish to set forth the terms and
conditions upon which the Company will sell the Common Stock to the Purchaser;
and

      D. Concurrent with the execution of this Agreement, the Company and
Purchaser are entering into an amendment (the "Rights Agreement Amendment") to
the Company's Amended and Restated Investor Rights Agreement (the "Rights
Agreement") to provide Purchaser with certain rights and obligations thereunder
upon the issuance of the Common Stock hereunder.

      NOW, THEREFORE, in consideration of the premises and mutual covenants and
conditions contained herein, the Company and the Purchaser hereby agree as
follows:

                                    ARTICLE I

                           PURCHASE AND SALE OF SHARES

      1.1 Purchase Price and Closing. Subject solely to the conditions set forth
in Sections 1.2 - 1.5 and Article IV hereof, the Company will issue and sell to
the Purchaser and, subject to the terms and conditions set forth in this
Agreement, the Purchaser will purchase from the Company (the "Sale"), that
number of shares of Common Stock (the "Shares") equal to the quotient obtained
by dividing Twenty-Five Million Dollars ($25,000,000) (the "Investment Amount")
by the per-share price to the public (the "IPO Price") of shares of Common Stock
in the Company's first underwritten, firm commitment public offering (the "IPO")
pursuant to an effective registration statement (the "Registration Statement")
under the Securities Act of 1933, as amended (the "Securities Act"). The per
share price to Purchaser shall be the IPO Price. The purchase and sale will take
place at a closing (the "Closing") to be held on the date, at the location and
simultaneously with the closing of the IPO, subject to the satisfaction of all
of the conditions to the Closing specified in Article IV herein. At the Closing
the Company will issue and deliver a certificate evidencing the Shares to the
Purchaser against payment of the full purchase price therefor by wire transfer
of immediately available funds to an account designated by the Company.

      1.2 Maximum Share Number. Notwithstanding Section 1.1 above, in the event
the number of Shares would otherwise constitute more than (i) nineteen and
nine-tenths percent (19.9%) of the Actual Voting Power (as defined in Section
5.1(i)) or (ii) twenty percent (20%) of the number of shares issued in the IPO
(including any shares covered by a related registration statement filed pursuant
to Rule 462(b) of

<PAGE>

the Securities Act but excluding any shares issued or to be issued in an
overallotment option), then in either case (i) or (ii) above the Investment
Amount (and correspondingly the number of shares purchased by the Purchaser)
shall be reduced by the minimum dollar amount and share amount necessary to
avoid either such event.

      1.3 Restrictions on Transfer. Pursuant to the Rights Agreement Amendment,
Purchaser agrees and acknowledges that the restrictions set forth in Sections
2.1 and 2.12 of the Rights Agreement shall apply to Purchaser and the Shares.

      1.4 HSR Act. Prior to the execution of the Collaboration Agreement and
this Agreement, the parties made certain filings under the Hart-Scott Rodino
Antitrust Improvements Act of 1976, as amended (the "HSR Act"). If either party
concludes in good faith that additional filings or proceedings are necessary or
desirable as a result of the transactions contemplated hereby either as a result
of the signing of this Agreement or in connection with the Closing or otherwise,
the parties agree to promptly file such additional notices, applications and
documents that may be required under the HSR Act, or any other required foreign
or domestic competition law (collectively, the "Competition Laws") and all
applicable additional filings fees associated therewith shall be paid by the
party required to so pay such additional filing fees under the applicable
Competition Law(s). In connection therewith, the Company and Purchaser each
shall use their commercially reasonable efforts to take such actions as may be
required to cause the expiration or early termination of the notice periods
under the Competition Laws as promptly as possible and to resolve such
objections, if any, as may be asserted with respect to the transactions
contemplated by this Agreement under the Competition Laws; provided, however,
that notwithstanding the foregoing, neither party shall agree to any change or
amendment to this Agreement unless such change or amendment is agreed by the
other party in advance. Nothing in this Agreement shall require either party or
any subsidiary or affiliate of either party to sell, hold separate, license or
otherwise dispose of any assets or conduct its business in a specified manner,
or agree or proffer to sell, hold separate, license or otherwise dispose of any
assets or conduct its business in a specified manner, or permit or agree to the
sale, holding separate, licensing or other disposition of any assets of either
party or any subsidiary or affiliate of either party, whether as a condition to
obtaining any approval from, or to avoid potential litigation or administrative
action by, a governmental entity or any other person or for any other reason.

      1.5 Termination of Purchase Right and Obligation. Notwithstanding any
provision of this Agreement to the contrary, Purchaser's right and obligation to
purchase, and the Company's right and obligation to sell, the Shares shall
terminate if the closing of the IPO has not occurred prior to the earliest to
occur of the following:

            (a) The termination of the Collaboration Agreement; or

            (b) The Company (1) undergoes a Change of Control (as defined in
Section 5.1(iv));; provided, however, the following shall be deemed to not be a
Change of Control for purposes of this Section 1.5(b): (i) a transaction
effected exclusively for the purpose of changing the domicile of the Company, or
(ii) an equity financing in which the Company is the surviving corporation, or
(2) engages in a merger, consolidation, reorganization or similar transaction in
which the surviving entity has a class of equity securities registered under
Section 12 of the Exchange Act (as defined below).

                                       2
<PAGE>

                                   ARTICLE II

                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

      The Company hereby represents and warrants to the Purchaser as follows:

      2.1 Corporate Action. The Company has all necessary corporate power and
has taken all corporate action required to enter into and perform this Agreement
and the Rights Agreement Amendment (collectively, the "Financing Documents").
The Financing Documents have been duly executed and delivered, and constitute
valid, legal, binding and enforceable obligations of the Company, enforceable in
accordance with their terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors' rights generally and (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other
equitable remedies. The issuance, sale and delivery of the Shares in accordance
with this Agreement have been duly authorized by all necessary corporate action
on the part of the Company. The issuance of the Shares is not subject to
preemptive rights or other preferential rights in any present stockholders of
the Company that have not been waived and will not conflict with any provision
of any agreement or instrument to which the Company is a party or by which it or
its property is bound and to which the Company has not obtained appropriate
waivers.

      2.2 No Conflict. The execution and delivery of this Agreement by the
Company does not, and the consummation of the transactions contemplated hereby
will not, conflict with, or result in any violation of, or default under (with
or without notice or lapse of time, or both), or give rise to a right of
termination, cancellation, modification or acceleration of any obligation under
(i) any provision of the Certificate of Incorporation of the Company or Bylaws
of the Company, (ii) any material mortgage, indenture, lease, contract or other
agreement or instrument, permit, concession, or license to which the Company or
any of its properties or assets is subject or (iii) any judgment, order, decree,
applicable to the Company or its properties or assets. To the Company's
knowledge as of the date hereof, no provision of any applicable law, rule or
regulation and no judgment, order, decree or injunction applicable to the
Company or its properties or assets shall prohibit the consummation of the
Closing nor shall the Closing result in any violation of any such law, rule,
regulation, judgment, order, decree or injunction.

      2.3 Status of Shares. The Shares, when issued and delivered in accordance
with the terms hereof and after payment of the purchase price therefor, will be
duly authorized, validly issued, fully-paid and non-assessable, issued in
compliance with applicable state and federal securities laws (subject, in part,
to the representations and warranties of Purchase in Article III hereof) and
free of restrictions on transfer other than restrictions on transfer under the
Financing Documents and applicable state and federal securities laws.

      2.4 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
carry on its business.

      2.5. Collaboration Agreement. The Collaboration Agreement has been duly
authorized, executed, and delivered by the Company and constitutes a valid and
binding obligation of the Company, enforceable in accordance with its terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of
creditors' rights generally and (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable
remedies.

                                       3
<PAGE>

      2.6 Final Prospectus and Registration Statement. The Company,
acknowledging that the Purchaser will be relying on the accuracy and
completeness of the Company's disclosure in connection with the IPO, warrants to
the Purchaser that the Prospectus (as defined below) used in connection with the
Company's IPO will comply, at the time of filing or use, with the requirements
of the Securities Act, and the Prospectus filed or used in connection with the
IPO will not, at such time, contain an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were
made, not misleading; the Registration Statement, when it becomes effective,
will comply, in all material respects, with the requirements of the Securities
Act; and the Registration Statement will not, when it becomes effective, contain
an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein; provided,
however, that the Company makes no warranty with respect to any statement
contained in the Registration Statement or a prospectus in reliance upon and in
conformity with information concerning the Purchaser that is furnished by the
Purchaser expressly for use therein. "Prospectus" means the final prospectus (as
such term is defined in Section 2(a)(10) of the Securities Act) as first filed
with the SEC pursuant to paragraph (1) or (4) of Rule 424(b) of the Securities
Act.

                                   ARTICLE III

            REPRESENTATIONS AND WARRANTIES AND COVENANTS BY PURCHASER

      The Purchaser represents and warrants and covenants to the Company that:

      3.1 Purchaser is an "accredited investor" as defined in Rule 501(a) under
the Securities Act of 1933, as amended.

      3.2 Purchaser will acquire the Shares for its own account, for the purpose
of investment and not with a view to distribution or resale thereof.

      3.3 Purchaser has all necessary corporate power and has taken all
corporate action required to enter into and perform the Financing Documents. The
Financing Documents have been duly executed and delivered, and constitute valid,
legal, binding and enforceable obligations of Purchaser, enforceable in
accordance with their terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors' rights generally and (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other
equitable remedies.

      3.4 Purchaser has taken no action which would give rise to any claim
against the Company by any other person for any brokerage commissions, finders'
fees or the like relating to this Agreement or the transactions contemplated
hereby.

      3.5 Purchaser has had the opportunity to ask questions of and receive
answers from representatives of the Company concerning the terms of the offering
of the Shares and to obtain additional information concerning the Company and
its business.

      3.6 The acquisition by the Purchaser of the Shares shall constitute a
confirmation of these representations and warranties made by the Purchaser as of
the Closing. Purchaser understands that the Shares are "restricted securities"
under the Securities Act and have not been registered under the Securities Act
in reliance upon an exemption for non-public offerings. The Purchaser further
represents that it understands and agrees that, until registered under the
Securities Act or transferred pursuant to the provisions of Rule 144 as
promulgated by the Commission, all certificates evidencing any of the Shares,

                                       4
<PAGE>

whether upon initial issuance or upon any transfer thereof, shall be subject to
the transfer restrictions and bear the legends set forth in Section 2.1 of the
Rights Agreement.

      3.7 To the Purchaser's knowledge as of the date hereof, no provision of
any applicable law, rule or regulation and no judgment, order, decree or
injunction applicable to the Purchaser or its properties or assets shall
prohibit the consummation of the Closing nor shall the Closing result in any
violation of any such law, rule, regulation, judgment, order, decree or
injunction.

                                   ARTICLE IV

                              CONDITIONS TO CLOSING

      4.1 Conditions of the Purchaser's Obligation. The obligation of the
Purchaser to purchase and pay for the Shares at the Closing is subject to the
satisfaction of the following conditions:

            (a) Documentation at Closing. The Purchaser shall have received
prior to or at the Closing all of the following documents or instruments, or
evidence of completion thereof, each in form and substance satisfactory to the
Purchaser:

                  (i) A copy of the Certificate of Incorporation of the Company,
certified by the Secretary of State of the State of Delaware, a copy of the
resolutions of the Board of Directors of the Company evidencing the approval of
this Agreement, the issuance of the Shares and the other matters contemplated
hereby, and a copy of the Bylaws of the Company, all of which shall have been
certified by the Secretary of the Company to be true, complete and correct in
every particular, and certified copies of all documents evidencing other
necessary corporate or other action and governmental approvals, if any, with
respect to this Agreement and the Shares.

                  (ii) A customary opinion of counsel to the Company covering
the matters set forth in Exhibit A hereto.

                  (iii) A certificate of the Secretary of the Company which
shall certify the names of the officers of the Company authorized to sign this
Agreement, the certificate for the Shares and the other documents, instruments
or certificates to be delivered pursuant to this Agreement by the Company or any
of its officers, together with the true signatures of such officers.

                  (iv) A certificate of the President of the Company stating (A)
that the representations and warranties made by the Company in this Agreement
are true and correct in all material respects at the date hereof and as of the
Closing with the same force and effect as though all such representations and
warranties had been made as of the Closing, and (B) that all covenants and
conditions required to be performed prior to or at the Closing have been
performed as of the Closing.

                  (v) A Certificate of Good Standing for the Company from the
Secretary of State of the State of Delaware, dated as of a recent date.

            (b) Performance. The Company shall have performed and complied with
in all material respects all agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by it on or
before the Closing.

            (c) Consents, Waivers, Etc. The Company shall have obtained all
consents or waivers, if any, necessary to execute and deliver this Agreement,
issue the Shares and to carry out the transactions contemplated hereby and
thereby and the waiting period applicable to this Agreement and the

                                       5
<PAGE>

Collaboration Agreement under the HSR Act (or any other applicable Competition
Laws) shall have expired or terminated early. All corporate and other action and
governmental filings necessary to effect the terms of this Agreement, the
issuance of the Shares and other agreements and instruments executed and
delivered by the Company in connection herewith shall have been made or taken,
except for any post-sale filing that may be required under federal or state
securities laws.

            (d) Rights Agreement Amendment. The Rights Agreement Amendment shall
have been executed by the Company and by the holders of the requisite majority
of Registrable Securities (as such term is defined in the Rights Agreement);
provided, however, the parties acknowledge that subsequent to the date hereof
the Rights Agreement may be further amended in accordance with its terms;
provided, further, however, Purchaser shall be required to consent to such
amendment or be provided substantially equivalent rights in such amendment or
another written agreement with the Company.

            (e) Collaboration Agreement. The Collaboration Agreement shall have
been duly authorized, executed, and delivered by the Company and constitute a
valid and binding obligation of the Company, enforceable in accordance with its
terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other
equitable remedies. The Purchaser shall not have the right to terminate the
Collaboration Agreement for cause pursuant to Section 9.5 thereof (provided,
however, if Purchaser's right to so terminate the Collaboration Agreement for
cause is solely dependent on the lapsing on any applicable "cure" period
pursuant to Section 9.5 thereof, solely for purposes of this Section 4.1(e),
Purchaser shall be deemed to have the right to terminate the Collaboration
Agreement for cause notwithstanding the failure of any such cure period to have
lapsed); and the Company shall not have given notice to the Purchaser of its
intent to terminate the Collaboration Agreement.

            (f) Representations and Warranties. The representations and
warranties made by the Company in this Agreement shall have been true and
correct in all material respects at the date hereof and as of the Closing with
the same force and effect as though all such representations and warranties had
been made as of the Closing.

            (g) No Injunctions. No provision of any applicable law, rule or
regulation and no judgment, order, decree or injunction shall prohibit the
consummation of the Closing.

            (h) Listing. The shares of Common Stock sold in the IPO shall be
listed on the New York Stock Exchange ("NYSE") or traded on the Nasdaq National
Market.

            (i) Closing of IPO. The Closing hereunder shall be concurrent with
the closing of the IPO.

      4.2 Conditions of the Company's Obligation. The obligation of the Company
to sell the Shares at the Closing is subject to the satisfaction of the
following conditions:

            (a) Performance. The Purchaser shall have performed and complied
with in all material respects all agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with
by it on or before the Closing.

            (b) Consents, Waivers, Etc. Any waiting period applicable to this
Agreement and the Collaboration Agreement under the HSR Act (or any other
applicable Competition Laws) shall have expired or terminated early.

                                       6
<PAGE>

            (c) Rights Agreement Amendment. The Rights Agreement Amendment shall
have been executed by the Purchaser.

            (d) Collaboration Agreement. The Collaboration Agreement shall have
been duly authorized, executed and delivered by the Purchaser and constitute a
valid and binding obligation of the Purchaser, enforceable in accordance with
its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific
performance, injunctive relief or other equitable remedies. The Company shall
not have the right to terminate the Collaboration Agreement for cause pursuant
to Section 9.5 thereof (provided, however, if the Company's right to so
terminate the Collaboration Agreement for cause is solely dependent on the
lapsing on any applicable "cure" period pursuant to Section 9.5 thereof, solely
for purposes of this Section 4.2(d), the Company shall be deemed to have the
right to terminate the Collaboration Agreement for cause notwithstanding the
failure of any such cure period to have lapsed; and the Purchaser shall not have
given notice to the Company of its intent to terminate the Collaboration
Agreement.

            (e) Representations and Warranties. The representations and
warranties made by the Purchaser in this Agreement shall have been true and
correct in all material respects at the date hereof and as of the Closing with
the same force and effect as though all such representations and warranties had
been made as of the Closing.

            (f) No Injunctions; Applicable Law. No provision of any applicable
law, rule or regulation and no judgment, order, decree or injunction shall
prohibit the consummation of the Closing nor shall the Closing result in any
violation of any such law, rule, regulation, judgment, order, decree or
injunction.

            (g) Listing. The shares of Common Stock sold in the IPO shall be
listed on the NYSE or traded on the Nasdaq National Market.

            (h) Closing of IPO. The Closing hereunder shall be concurrent with
the closing of the IPO.

            (i) Securities Regulations. The sale of the Shares to Purchaser
shall not be prohibited under state and federal securities laws and regulations.

                                    ARTICLE V

                              STANDSTILL AGREEMENT

      5.1. Definitions. For the purposes of this Agreement, the following words
and phrases shall have the following meanings:

            (i) "Actual Voting Power" means, as of the date of determination,
the total number of votes attaching to the outstanding securities entitled to
vote for the election of directors of the Company.

            (ii) "Affiliate" shall have the meaning given it in Rule 12b-2 under
the Securities Exchange Act of 1934, as amended (the "Exchange Act").

            (iii) "Beneficial Ownership" "Beneficial Owner" and "Beneficially
Own" shall have the meanings described to those terms in Rule 13d-1 under the
Exchange Act.

                                       7
<PAGE>

            (iv) "Change of Control" means (1) the acquisition by a Third Party
of more than 50% of the Company's then outstanding Voting Securities or (2) the
consummation of a merger, acquisition, consolidation or reorganization or series
of such related transactions involving the Company, unless immediately after
such transaction or transactions, the Beneficial Owners of the Company
immediately prior to the first such transaction shall Beneficially Own at least
50% of the outstanding Voting Securities of the Company (or, if the Company
would not be the surviving company in such merger, consolidation or
reorganization, the Voting Securities of the surviving corporation issued in
such transaction or transactions in respect of Voting Securities of the Company
shall represent at least 50% of the Voting Securities of such surviving
company).

            (v) "Investor Group" means Purchaser and any member of a 13D Group
to which the Purchaser belongs.

            (vi) "Person" means an individual, corporation, partnership,
association, trust, unincorporated organization or other entity

            (vii) "13D Group" means any group of persons formed for the purpose
of acquiring, holding, voting or disposing of Voting Securities which would be
required under the Exchange Act and the rules and regulations promulgated
thereunder, to file a statement on Schedule 13D with the Securities and Exchange
Commission as a "person" within the meaning of Section 13(d)(3) of the Exchange
Act if such group beneficially owned sufficient securities to require such a
filing under the Exchange Act.

            (viii) "Standstill Period" shall mean the period beginning on the
Closing of the IPO and ending on the date that is one year following the Closing
of the IPO.

            (ix) "Threshold Percentage" means the percentage of Actual Voting
Power owned by the Purchaser immediately following the closing of the IPO and
the sale of Shares hereunder, which in no case shall exceed nineteen and
nine-tenths percent (19.9%) of Actual Voting Power.

            (x) "Third Party" means any Person or two or more Persons acting in
concert, other than the Purchaser and its Affiliates or the Company and its
Affiliates.

            (xii) "Voting Security" means, as of the date of determination, the
Common Stock of the Company, any other security generally entitled to vote for
the election of directors and any outstanding convertible securities, options,
warrants or other rights which are convertible into or exchangeable or
exercisable for securities entitled to vote for the election of directors.

      5.2. Standstill Obligations.

            (a) Limitation. At any time during the Standstill Period, except
with the prior written consent of the Company's Board of Directors, no member of
the Investor Group shall, directly or indirectly:

            (i) acquire any Voting Securities (except by way of stock splits,
stock dividends or other distributions) if the effect of such acquisition or
exercise would be to increase the percentage interest of the Investor Group in
the Actual Voting Power to more than the Threshold Percentage; or

            (ii) publicly propose (on behalf of itself or to or with a Third
Party) any merger, business combination, restructuring, recapitalization or
similar transaction involving the Company or its subsidiaries or the purchase,
sale or other disposition outside the ordinary course of business of any
material portion of the assets of the Company or any of its subsidiaries.

                                       8
<PAGE>

            (b) Repurchases. Notwithstanding Section 5.2(a), no member of the
Investor Group shall be obligated to dispose of any Voting Securities if the
aggregate percentage ownership of the Investor Group is increased as a result of
a repurchase of Voting Securities by the Company.

            (c) Participation. Except with the prior written consent of the
Company's Board of Directors, during the Standstill Period the Investor Group
will not:

                  (i) solicit proxies (or powers of attorney or similar rights
to vote) in respect of any Voting Securities;

                  (ii) become a "participant" or "participant in a
solicitation", as those terms are defined in Regulation 14A of the General Rules
and Regulations promulgated pursuant to the Exchange Act, in opposition to a
solicitation by the Company; provided, however, that the Investor Group shall
not be deemed to be a "participant" or to have become engaged in a solicitation
hereunder solely by reason of the Company's solicitation of proxies in
connection with any meeting of the stockholders of the Company;

                  (iii) seek to advise or intentionally influence any person or
entity with respect to the voting of Voting Securities in connection with any
such solicitation, in opposition to the recommendation of a majority of the
Board of Directors with respect to any matter relating to a Change of Control;

                  (iv) initiate, propose or otherwise solicit stockholders for
the approval of any stockholder proposal (as described in Rule 14a-8 under the
Exchange Act or otherwise) with respect to the Company that is opposed by the
Board of Directors;

                  (v) form or join any 13D Group for the purpose of voting,
purchasing or disposing of Voting Securities or the acquisition of all or
substantially all of assets of the Company;

                  (vi) deposit any Voting Securities in a voting trust or
subject them to a voting agreement or other arrangement of similar effect,
except in order to comply with Competition Laws or other legal requirements;

                  (vii) otherwise act, alone or in concert with others, in a
manner designed or having the deliberate effect of circumventing the
restrictions otherwise imposed hereunder, publicly announce any intention, plan
or arrangement inconsistent with the foregoing or finance or agree to finance
any other person in connection with any of the activities prohibited by this
Agreement; or

                  (viii) publicly request, propose or otherwise seek any
amendment or waiver of the provisions of this Article 5.

      5.3 Exceptions. The limitations provided in Section 5.2 shall immediately
terminate upon the occurrence of any of the following events:

            (a) the commencement by any Person (other than a member of the
Investor Group or an Affiliate thereof) of a bona fide tender or exchange offer
seeking to acquire Beneficial Ownership of fifty percent (50%) or more of the
outstanding shares of Voting Securities of the Company;

            (b) the execution of an agreement by the Company and any Person
which, if consummated, would result in either (i) a Change of Control of the
Company or (ii) the sale of all or substantially all of the Company's assets; or

                                       9
<PAGE>

            (c) the adoption by the Company of a plan of liquidation or
dissolution with respect to the Company.

      5.4 Exclusion. No action or actions taken by the Purchaser pursuant to the
terms of the Collaboration Agreement or in connection with exercising or
enforcing its rights thereunder shall be deemed to violate the restrictions in
Section 5.2.

                                   ARTICLE VI

                                  MISCELLANEOUS

      6.1 No Waiver. No failure or delay on the part of any party to this
Agreement in exercising any right, power or remedy hereunder shall operate as a
waiver thereof; nor shall any single or partial exercise of any such right,
power or remedy preclude any other or further exercise thereof or the exercise
of any other right, power or remedy hereunder. None of the terms, covenants and
conditions of this Agreement can be waived except by the written consent of the
party waiving compliance.

      6.2 Publicity. The parties may, subject to compliance with the Securities
Act, issue a joint press release announcing this Agreement and the transactions
contemplated hereby following execution of this Agreement. Any proposed
announcement, press release or other public disclosure concerning this Agreement
and/or any of the transactions or relationships contemplated hereby shall be
mutually approved by both parties (which approval shall not be unreasonably
withheld); provided, however, that the restrictions contained in this Section
6.2 do not apply to disclosures required by law, the rules of the NYSE, the NASD
or under U.S. generally accepted accounting principles. The Purchaser agrees and
acknowledges that this Agreement and the transactions contemplated hereby shall
be disclosed in, and filed as an exhibit to, the Registration Statement.

      6.3 Amendments, Waivers and Consents. Any provision in this Agreement to
the contrary notwithstanding, and except as hereinafter provided, changes in or
additions to this Agreement may be made, and compliance with any covenant or
provision set forth herein may be omitted or waived, if the party requesting
such change, addition, omission or waiver shall obtain consent thereto in
writing from the other party. Any waiver or consent may be given subject to
satisfaction of conditions stated therein and any waiver or consent shall be
effective only in the specific instance and for the specific purpose for which
given. Any such amendment or waiver or consent effected in accordance with this
Section 6.3 shall be binding upon the parties and their respective successors
and assigns.

      6.4 Addresses for Notices. Any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient upon receipt, when
delivered personally or by courier, overnight delivery service or confirmed
facsimile, or seventy-two (72) hours after being deposited in the regular mail
as certified or registered mail (airmail if sent internationally) with postage
prepaid, if such notice is addressed to the party to be notified at such party's
address or facsimile number as set forth below, or as subsequently modified by
written notice.

      If to the Company:

             Trubion Pharmaceuticals, Inc.
             2401 Fourth Avenue, Suite 1050
             Seattle, WA  98121
             Attn:  Chief Executive Officer and General Counsel
             Facsimile Number:  (206) 838-0503

                                       10
<PAGE>

      If to the Purchaser:

             Wyeth Pharmaceuticals
             500 Arcola Road
             Collegeville, Pennsylvania  19426
             Attn: Senior Vice President, Corporate Business Development
             Fax:  (484) 865-6476

             with a copy to:

             Wyeth
             5 Giralda Farms
             Madison, NJ  07940
             Attn:  Executive Vice President and General Counsel
             Facsimile:  (973) 660-7156

      6.5 Binding Effect; Assignment. This Agreement may not be assigned by
either party without the prior written consent of the other; provided, however,
that the Purchaser may assign its rights and delegate its duties hereunder to an
Affiliate without the prior written consent of the Company; provided, however,
Purchaser shall remain subject to Section 5 hereof regardless of any such
assignment; and provided further that if the Company undergoes a Change of
Control in which (a) the Company is not the surviving entity and (b) this
Agreement does not terminate pursuant to Section 1.5(b) in connection with such
Change of Control, the surviving entity and the Purchaser shall enter into a
replacement agreement with substantially the same terms as this Agreement.
Subject to the foregoing, the terms and conditions of this Agreement shall inure
to the benefit of and be binding upon the respective successors and assigns of
the parties. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under
or by reason of this Agreement, except as expressly provided in this Agreement.

      6.6 Entire Agreement. This Agreement and the documents referred to herein
constitute the entire agreement between the parties and supersede any prior
understandings or agreements concerning the subject matter hereof.

      6.7 Specific Performance. The parties acknowledge and agree that
irreparable damage would occur in the event any of the provisions of Article V
of this Agreement were not performed in accordance with their specific terms or
were otherwise breached. Accordingly, it is agreed that the parties shall be
entitled to an injunction or injunctions to prevent or cure breaches of the
provisions of Article V of this Agreement and to enforce specifically the terms
and provisions of such Article in any court of the United States or any state
thereof having jurisdiction, in addition to any other remedy to which they may
be entitled in law or in equity.

      6.8 Severability. The provisions of this Agreement are severable and, in
the event that any court of competent jurisdiction shall determine that any one
or more of the provisions or part of a provision contained in this Agreement
shall, for any reason, be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other provision or part of a provision of this Agreement; but this Agreement,
shall be reformed and construed as if such invalid or illegal or unenforceable
provision, or part of a provision, had never been contained herein, and such

                                       11
<PAGE>

provisions or part reformed so that it would be valid, legal and enforceable to
the maximum extent possible.

      6.9 Governing Law. This Agreement shall be governed by, and construed and
enforced in accordance with, the laws of the State of Delaware without reference
to Delaware conflicts of law provisions.

      6.10 Headings. Article, Section and subsection headings in this Agreement
are included herein for convenience of reference only and shall not constitute a
part of this Agreement for any other purpose.

      6.11 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be enforceable against the party actually
executing the counterpart, and all of which together shall constitute one
instrument.

                            [Signature page follows.]

                                       12
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first above written.

                                   TRUBION PHARMACEUTICALS, INC.

                                   By:      /s/ Peter A. Thompson
                                   Name:    Peter A. Thompson
                                   Title:   President & Chief Executive Officer

                                   WYETH

                                   By:      /s/ William M. Haskel
                                   Name:    William M. Haskel
                                   Title:   Vice President

                 SIGNATURE PAGE TO TRUBION PHARMACEUTICALS, INC.
                         COMMON STOCK PURCHASE AGREEMENT
<PAGE>
                                                                       EXHIBIT A

                    MATTERS TO BE COVERED BY COMPANY COUNSEL

      1. The Company is a corporation validly existing under Delaware law and in
good standing with the Secretary of the State of Delaware and has the corporate
power to execute and deliver the Agreement and to perform its obligations
thereunder.

      2. The Company has duly authorized, executed and delivered the Agreement,
and the Agreement constitutes the Company's valid and binding agreement
enforceable against the Company in accordance with its terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or affecting creditors' rights generally
or by general equitable principles.

      3. No consent, approval, authorization or order of, or any filing or
declaration with, any court or governmental agency or body is required in
connection with the execution, delivery and performance of the Agreement by the
Company or in connection with the taking by the Company of any action
contemplated thereby, other than as indicated in the Agreement or such as have
been obtained and made and such as may be required under federal and state
securities laws.

      4. The execution, delivery and performance of the Agreement by the
Company, and the consummation by the Company of the transactions contemplated
therein do not and will not (a) violate the Certificate of Incorporation or
By-Laws of the Company, (b) materially violate any judgment, ruling, decree or
order known to such counsel, (c) materially violate any statute or regulation
applicable to the business or properties of the Company, or (d) result in a
material breach or violation of any of the terms or provisions of, or constitute
a default or result in the acceleration of any obligation under any material
contract to which the Company is a party or bound.

      5. The Shares delivered on the date hereof have been duly authorized and
validly issued and are fully paid and non-assessable shares of the Company.

                SIGNATURE PAGE TO TRUBION PHARMACEUTICALS, INC.
                        COMMON STOCK PURCHASE AGREEMENT<PAGE>

                                                                   Exhibit 10.13

                          DEVELOPMENT AND MANUFACTURING

                               SERVICES AGREEMENT

                                     BETWEEN

                               LONZA BIOLOGICS ***

                                       AND

                                 GENECRAFT INC.

<PAGE>

     THIS AGREEMENT is made the 12th day of August, 2003 (the "Effective Date")

     BETWEEN

     1. LONZA BIOLOGICS ***, the registered office of which is at *** (herein
after referred to as "LB"), and

     2. GENECRAFT INC., the registered office of which is at 2401 4th Ave.,
Suite 1050, Seattle, WA 98121 USA (herein after referred to as the "Customer").

     WHEREAS

     A. The Customer has created or controls certain Cell Lines as defined
herein; and

     B. LB has expertise in the evaluation and production of monoclonal
antibodies and proteins for therapeutic use using such Cell Lines; and

     C. The Customer wishes to contract LB for Services relating to the Cell
Line as described in the Agreement, and

     D. LB is prepared to perform such Services for the Customer under the terms
and conditions set out herein.

     NOW IT IS AGREED AS FOLLOWS:

     1. The following terms shall have the following meanings unless the context
requires otherwise:

     "Affiliate" means any Company, partnership or other entity which directly
or indirectly Controls, is Controlled by or is under common Control with the
relevant party to this Agreement. "Control" means the ownership of more than
fifty percent (50%) of the issued share capital or the legal power to direct or
cause the direction of the general management and policies of the party in
question;

     "Agreement" means this agreement incorporating Schedules 1 (Definitions and
Specifications), 2 (Services) and 3 (Price and Terms of Payment) as amended or
varied from time to time by written agreement of the parties;

     "Cell Line" means the cell line provided by Customer to LB, particulars of
which are set out in Schedule 1;

     "Customer" means GENECRAFT INC and its successors in title and lawful
assigns;

     "Customer Information" means all technical and other information not known
to LB or in the public domain relating to the Cell Line, the Process (including
for the avoidance of doubt improvements or modifications thereto from time to
time) and the Product, from time to time supplied by the Customer to LB;

<PAGE>

     "Customer Materials" means the materials supplied by Customer to LB (if
any) and identified as such by Schedule 1 hereto;

     "Customer Patent Rights" means all patents and patent applications of any
kind throughout the world that are necessary or useful in performance of the
Services excluding the LB Patent Rights;

     "Deliver", "Delivered" or "Delivery" has the meaning given to it in Clause
4.1;

     "LB Know-How" means all technical and other information relating directly
or indirectly to the Process known to LB from time to time other than
confidential Customer Information and information in the public domain;

     "LB Patent Rights" means all patents and patent applications of any kind
throughout the world relating to the Process which from time to time LB is the
owner of or is entitled to use;

     "Price" means the price specified in Schedule 3 for the Services;

     "Process" means the process for the production of the Product from the Cell
Line, including any improvements or modifications thereto from time to time;

     "Product" means all or any part of the product manufactured using the
Process (including any sample thereof), particulars of which are set out in
Schedule 1 and includes all derivatives thereof;

     "Services" means all or any part of the services performed by LB under the
Agreement (including, without limitation, cell culture evaluation, purification
evaluation, master, working and extended cell bank creation, and sample and bulk
production), particulars of which are set out in Schedule 2;

     "Terms of Payment" means the terms of payment specified in Schedule 3.

     References to the singular number include the plural and vice versa,
references to Clauses and Schedules are references to clauses and schedules to
this Agreement.

     2. CUSTOMER OBLIGATIONS, WARRANTIES AND INDEMNITIES

          2.1 Customer shall pay the Price set out in Schedule 3 for provision
of the Services together with any additional costs and expenses mutually agreed
upon by the parties that fall due under this Agreement in accordance with the
Terms of Payment.

          2.2 As agreed by the parties, the Customer shall supply to LB the
Customer Information, together with full details of any hazards known to
Customer relating to the Cell Line and/or the Customer Materials, and their
storage and use. On review of this Customer Information, the Cell Line and/or
the Customer Materials shall be provided to LB at LB's request. All right,
title, and interest in and to the Cell Line and/or the Customer Materials and/or
the Customer Information supplied to LB shall remain vested in the Customer.

                                      -2-

<PAGE>

          2.3 Subject to the terms and conditions of this Agreement, the
Customer hereby grants LB the non-exclusive, non-transferable (other than to
LB's Affiliates), right to use the Cell Line, the Customer Materials and the
Customer Information during the term of this Agreement solely for the purpose of
the Agreement.

          2.4 The Customer warrants to LB that:

               2.4.1 Customer has the right to enter into this Agreement;

               2.4.2 ***;

               2.4.3 ***;

               2.4.4 ***;

               2.4.5 ***.

          2.5 The Customer undertakes to indemnify and to maintain LB promptly
indemnified against any loss, damage, costs and expenses of any nature
(including court costs and legal fees on a full indemnity basis), whether direct
or consequential, and whether or not foreseeable or in the contemplation of LB
or the Customer, that LB may ***.

          2.6 The Customer shall further indemnify and maintain LB promptly
indemnified against all claims, actions, costs, expenses (including court costs
and legal fees on a full indemnity basis) or other liabilities whatsoever in
respect of:

               2.6.1 ***; and

               2.6.2 ***.

          2.7 The obligations of the Customer under this Clause 2 shall survive
the termination for whatever reason of the Agreement.

     3. Provision of the Services

          3.1 LB shall diligently carry out the Services as provided in Schedule
2 and shall use all reasonable efforts to achieve the estimated timescales set
out in that Schedule.

          3.2 LB shall manufacture Product using *** as outlined in Schedule 2,
Stage 1.

          3.3 Owing to the unpredictable nature of the biological processes
involved in the Services, the timescales set down for the performance of the
Services (including without limitation the dates for production and Delivery of
Product) and the quantities of Product for Delivery set out in Schedule 2 are
estimated only.

          3.4 Without prejudice to LB's obligations under Clauses 3.1 and 3.2,
***:

               3.4.1 ***; or

                                      -3-

<PAGE>

               3.4.2 ***.

     Provided that if a significant failure to perform the Services or produce
the Product for Delivery arises due to gross negligence by LB the parties shall
agree a commercially reasonable mechanism by which to compensate Customer.

          3.5 LB shall comply with the International Committee for Harmonisation
regulatory requirements from time to time applicable to the Services as set out
in Schedule 2.

          3.6 LB hereby undertakes not to use the Cell Line, the Customer
Materials or the Customer Information (or any part thereof) for any purpose
other than to perform the Services and supply Product under this Agreement.

          3.7 LB shall:

               3.7.1 at all times use *** to keep the Cell Line and/or the
Customer Materials secure and safe from loss and damage in such manner as LB
!stores its own material of similar nature;

               3.7.2 not part with possession of the Cell Line and/or the
Customer Materials or the Product, save for the purpose of tests at the Testing
Laboratories; and

               3.7.3 procure that all Testing Laboratories are subject to
obligations of confidence substantially in the form of those obligations of
confidence imposed on LB under this Agreement.

     4. DELIVERY, TRANSPORTATION OF PRODUCT AND CUSTOMER TESTS

          4.1 Product shall be *** and (b) risk and title to Product pass to
Customer upon Delivery ("Deliver," "Delivery," or "Delivered," as appropriate).

          4.2 Unless otherwise agreed, LB shall package and label Product for
Delivery in accordance with its standard operating procedures. It shall be the
responsibility of the Customer to inform LB in writing in advance of any special
packaging and labelling requirements for Product. All additional costs and
expenses of whatever nature incurred by LB in complying with such special
requirements shall be charged to the Customer in addition to the Price.

          4.3 If requested in writing by the Customer, LB will (acting as agent
for Customer) arrange for insurance of Product whilst held by LB after Delivery
(awaiting transportation) for a maximum of *** on terms equivalent to those
under which LB insures other comparable products prior to Delivery. All
additional costs and expenses of whatever nature incurred by LB in arranging
such insurance shall be charged to the Customer in addition to the Price.

          4.4 If requested in writing by the Customer, LB will (acting as agent
of the Customer for such purpose) arrange the transportation of Product from
LB's premises to the destination indicated by the Customer together with
insurance cover for Product in transit at its

                                      -4-

<PAGE>

invoiced value. All additional costs and expenses of whatever nature incurred by
LB in arranging such transportation and insurance shall be charged to the
Customer in addition to the Price.

          4.5 Where LB has made arrangements for the transportation of Product,
the Customer shall diligently examine the Product as soon as practicable after
receipt. Notice of all claims (time being of the essence) arising out of:

               4.5.1 visible damage to or total or partial loss of Product in
transit shall be given in writing to LB and the carrier within *** of receipt by
Customer; or

               4.5.2 non-Delivery shall be given in writing to LB within ***
after the date of LB's despatch notice.

          4.6 The Customer shall make damaged Product and associated packaging
materials available for inspection and shall comply with the requirements of any
insurance policy covering the Product notified by LB to the Customer. LB shall
offer the Customer all reasonable assistance (at the cost and expense of the
Customer) in pursuing any claims arising out of the transportation of Product.

     5. PRICE AND TERMS OF PAYMENT

          5.1 Unless otherwise indicated in writing by LB, all prices and
charges are exclusive of Value Added Tax or of any other applicable taxes,
levies, imposts, duties and fees of whatever nature imposed by or under the
authority of any government or public authority, which shall be paid by the
Customer (other than taxes on LB's income). All invoices are strictly net and
payment must be made within *** of date of invoice. Payment shall be made
without deduction, deferment, set-off, lien or counterclaim of any nature.

          5.2 In default of payment on due date:

               5.2.1 interest shall accrue on any amount overdue at the rate of
*** above the base lending rate from time to time of National Westminster Bank
plc, interest to accrue on a day to day basis both before and after judgment;
and

               5.2.2 LB shall, at its sole discretion, and without prejudice to
any other of its accrued rights, be entitled to suspend the provision of the
Services or to treat the Agreement as repudiated on not less than *** prior
notice in writing to Customer given at any time thereafter.

     6. LB Warranties and Indemnity

          6.1 LB warrants that:

               6.1.1 the Services shall be performed in accordance with Clause
3.1;

               6.1.2 unencumbered title (save for any intellectual property
rights which may exist) to Product will be conveyed to Customer upon Delivery;

                                      -5-

<PAGE>

               6.1.3 as of the date of this Agreement the LB Know-How and LB
Patent Rights are owned by LB or LB is otherwise entitled to use them for the
purposes of providing Services under this Agreement and during the term of this
Agreement LB shall not do or cause anything to be done which would adversely
affect their ownership or entitlement to use the same for those purposes;

               6.1.4 LB has the necessary corporate authorisations to enter into
this Agreement;

               6.1.5 as of the date of this Agreement to the best of LB' s
knowledge and belief, the use by LB of the Process (excluding any modifications
or steps made or developed by Customer, the Customer Materials, Customer
Information and Customer Patent Rights) and LB Patent Rights and LB Know-How for
the performance of the Services as provided herein will not infringe any rights
(including without limitation any intellectual or industrial property rights)
vested in any third party;

               6.1.6 LB will notify Customer in writing immediately if it
receives or is notified of a claim from a third party that the use by LB of the
Process and/or the LB Know-How or the LB Patent Rights for Services infringes
any intellectual property rights vested in such third party.

          6.2 Clause 6.1 is in lieu of all conditions, warranties and statements
in respect of the Services and/or the Product whether expressed or implied by
statute, custom of the trade or otherwise (including but without limitation any
such condition, warranty or statement relating to the description or quality of
the Product, its fitness or suitability for a particular purpose or use under
any conditions whether or not known to LB) and any such condition, warranty or
statement is hereby excluded.

          6.3 LB undertakes to indemnify and to maintain Customer promptly
indemnified against any direct loss, damage, costs and expenses (including court
costs and legal fees on a full indemnity basis) that Customer may suffer arising
directly out of any third party claim or action resulting from any breach of the
warranties given by LB in Clause 6.1 or any claims alleging that LB's sole use
of LB Know-How (excluding use of LB Know-How with Customer Materials or Customer
Information) infringes any rights (including without limitation any intellectual
or industrial rights) vested in a third party (whether or not LB knows or ought
to have known the same).

          6.4 Without prejudice to the terms of Clauses 4.5 6.3, 6.5 and 6.6,
the liability of LB for any loss or damage suffered by the Customer as a result
of any breach of the Agreement or of any other liability of LB (including
misrepresentation and negligence) in respect of the Services (including without
limitation the production and/or supply of the Product) shall be limited to the
payment by LB of damages which shall not exceed ***

          6.5 Subject to Clause 6.6, LB shall not be liable for the following
loss or damage howsoever caused (even if foreseeable or in the contemplation of
LB or the Customer):

               6.5.1 ***; or

                                      -6-

<PAGE>

               6.5.2 ***; and

               6.5.3 ***.

          6.6 Nothing contained in these Standard Terms shall purport to exclude
or restrict any liability for death or personal injury resulting directly from
negligence by LB in carrying out the Services or any liability for breach of the
implied undertakings of LB as to title.

          6.7 The obligations of the Customer and LB under this Clause 6 shall
survive the termination for whatever reason of the Agreement.

     7. Confidentiality

          7.1 The Customer acknowledges that LB Know-How and LB acknowledges
that Customer Information, Customer Materials and the Cell Line with which it is
supplied by the other pursuant to the Agreement ("Confidential Information") is
supplied, subject to Clause 7.5, in circumstances imparting an obligation of
confidence and each agrees to keep the other party's Confidential Information
secret and confidential and to respect the other's proprietary rights therein
and not at any time for any reason whatsoever to disclose or permit such
Confidential Information to be disclosed to any third party save as expressly
provided herein.

          7.2 The Customer and LB shall each procure that all their respective
employees, consultants, contractors and persons for whom it is responsible
having access to the other party's Confidential Information shall be subject to
the same obligations of confidence as the principals pursuant to Clauses 7.1 and
7,3 and shall be bound by secrecy agreements in support of such obligations.

          7.3 LB and the Customer each undertake not to disclose or permit to be
disclosed to any third party except LB's Affiliate Lonza Biologies, Inc
(including any contractors or consultants not previously approved in writing by
LB, such approval not to be unreasonably withheld or delayed), or otherwise make
use of or permit to be made use of (a) any trade secrets or Confidential
Information relating to the technology, business affairs or finances of the
other, any subsidiary, holding company or subsidiary or any such holding company
of the other, or of any suppliers, agents, distributors, licensees or other
customers of the other which comes into its possession under this Agreement or
(b) the commercial terms of this Agreement except to the extent that the same is
required to be disclosed pursuant to subpoena, court order, judicial process or
otherwise by law, provided the receiving party provides prompt notice to the
disclosing party of such requirement in order to give the disclosing party an
opportunity to timely seek a protective order or other appropriate judicial
relief. In the event the disclosing party is unable to obtain a protective order
or other appropriate judicial relief, the receiving party shall disclose only
that portion of the disclosing party's Confidential Information which is legally
required to be disclosed, and ensure that all such Confidential Information of
the disclosing party shall be redacted to the fullest extent permitted by law
prior to such disclosure and that the disclosing party shall be given an
opportunity to review the Confidential Information prior to its disclosure.

                                      -7-

<PAGE>

          7.4 The obligations of confidence referred to in this Clause 7 shall
not extend to any information which:

               7.4.1 is or becomes generally available to the public otherwise
than by reason of a breach by the recipient party of the provisions of this
Clause 7;

               7.4.2 is known to the recipient party and is at its free disposal
prior to its receipt from the disclosing party;

               7.4.3 is subsequently disclosed to the recipient party without
being made subject to an obligation of confidence by a third party;

               7.4.4 LB or the Customer may be required to disclose under any
statutory, regulatory or similar legislative requirement, subject to the
imposition of obligations of secrecy wherever possible in that relation; or

               7.4.5 is developed by any servant or agent of the recipient party
without access to or use or knowledge of the Confidential Information of the
disclosing party.

          7.5 The parties acknowledge that:

               7.5.1 without prejudice to any other rights and remedies that the
parties may have, the parties agree that the Confidential Information is
valuable and that damages may not be an adequate remedy for any breach of the
provisions of Clauses 7.1, 7.2, 7.3 and 7.4. The parties agree that the relevant
party will be entitled without proof of special damage to the remedies of an
injunction and other equitable relief for any actual or threatened breach by the
other party;

               7.5.2 the Customer shall not at any time have any right, title,
license or interest in or to LB Know-How, the LB Patent Rights or any other
intellectual property rights relating to the Process which are vested in LB or
to which LB is otherwise entitled; and

               7.5.3 LB acknowledges that save as provided herein LB shall not
at any time have any right, title, license or interest in or to the Customer
Information, Customer Materials, the Cell Line, Customer Patent Rights or any
other intellectual property rights vested in Customer or to which the Customer
is entitled,

          7.6 The obligations of LB and the Customer under this Clause 7 shall
survive the termination for whatever reason of the Agreement.

     8. TERMINATION

          8.1 If it becomes apparent to either LB or the Customer at any stage
in the provision of the Services that it will not be possible to complete the
Services for scientific or technical reasons, *** period shall be allowed for
good faith discussion and attempts to resolve such problems. If such problems
are not resolved within such period, LB and the Customer shall each have the
right to terminate the Agreement forthwith by notice in writing. In the event of
such termination, the Customer shall pay to LB ***.

                                      -8-

<PAGE>

          8.2 The parties may each terminate the Agreement forthwith by notice
in writing to the other party upon the occurrence of any of the following
events:

               8.2.1 if the other commits a material breach of the Agreement
(which shall include a breach of the warranties set out in Clauses 2 and 6
respectively) which in the case of a breach capable of remedy is not remedied
within *** of the receipt by the other of notice identifying the breach and
requiring its remedy; or

               8.2.2 if the other ceases for any reason to carry on business or
compounds with or convenes a meeting of its creditors or has a receiver or
manager appointed in respect of all or any part of its assets or is the subject
of an application for an administration order or of any proposal for a voluntary
arrangement or enters into liquidation (whether compulsorily or voluntarily) or
undergoes any analogous act or proceedings under foreign law.

          8.3 Upon the termination of the Agreement for whatever reason:

               8.3.1 LB shall cease all use of and promptly return to the
Customer all Customer Information and shall dispose of or return to the Customer
the Customer Materials (and where supplied by Customer the Cell Line) and any
materials therefrom, as directed by the Customer;

               8.3.2 the Customer shall promptly return to LB all LB Know-How it
has received from LB;

               8.3.3 the Customer shall not thereafter use or exploit the LB
Patent Rights or the LB Know-How in any way whatsoever;

               8.3.4 LB shall refund within *** of the effective date of such
termination all amounts paid to LB in excess of the amounts owed to LB if any,
pursuant to this Clause 8; and

               8.3.5 LB and the Customer shall do all such acts and things and
shall sign and execute all such deeds and documents as the other may reasonably
require to evidence compliance with this Clause 8.3.

          8.4 Termination of the Agreement for whatever reason shall not affect
the accrued rights of either LB or the Customer arising under or out of this
Agreement and all provisions which are expressed to survive the Agreement shall
remain in full force and effect

     9. FORCE MAJEURE

          9.1 If LB is prevented or delayed in the performance of any of its
obligations under the Agreement by Force Majeure and shall give written notice
thereof to the Customer specifying the matters constituting Force Majeure
together with such evidence as LB reasonably can give and specifying the period
for which it is estimated that such prevention or delay will continue, LB shall
be excused from the performance or the punctual performance of such obligations
as the case may be from the date of such notice for so long as such cause of
prevention or delay shall continue.

                                      -9-

<PAGE>

          9.2 The expression "Force Majeure" shall be deemed to include any
cause affecting the performance by LB of the Agreement arising from or
attributable to acts, events, acts of God, omissions or accidents beyond the
reasonable control of LB.

     10. GOVERNING LAW, JURISDICTION AND ENFORCEABILITY

          10.1 The construction, validity and performance of the Agreement shall
be governed by the laws of ***, and LB and the Customer submit to the
non-exclusive jurisdiction of ***.

          10.2 No failure or delay on the part of either LB or the Customer to
exercise or enforce any rights conferred on it by the Agreement shall be
construed or operate as a waiver thereof nor shall any single or partial
exercise of any right, power or privilege or further exercise thereof operate so
as to bar the exercise or enforcement thereof at any time or times thereafter.

          10.3 The illegality or invalidity of any provision (or any part
thereof) of the Agreement or these Standard Terms shall not affect the legality,
validity or enforceability of the remainder of its provisions or the other parts
of such provision as the case may be.

     11. NOTICES

          11.1 Any notice or other communication to be given under this
Agreement shall be delivered personally or sent by facsimile transmission, or if
facsimile transmission is not available, by first class pre-paid post addressed
as follows:

               11.1.1 If to Lonza Biologics to: Lonza Biologies ***
                                                ***
                                                ***
                                                ***
                                                ***
                                                ***

                      For the attention of:     ***

                      If to the Customer to:    GeneCraft Inc.,
                                                24014th Ave., Suite 1050
                                                Seattle, WA 98121
                                                USA
                                                Facsimile: 206-838-0503

                      For the attention of:     Kendall M. Mohler, Ph.D.
                                                Senior Vice President, R & D

     or to such other destination as either party hereto may hereafter notify to
the other in accordance with the provisions of this Clause 11.

                                      -10-

<PAGE>

          11.2 All such notices or other communications shall be deemed to have
been served as follows:

               11.2.1 if delivered personally, at the time of such delivery;

               11.2.2 if sent by facsimile, upon receipt of the transmission
confirmation slip showing completion of the transmission;

               11.2.3 if sent by first class pre-paid post, the earlier of
receipt by the addressee or ten (10) business days (Saturdays, Sundays and Bank
or other public holidays excluded) after being placed in the post.

     12. MISCELLANEOUS

          12.1 Neither party shall be entitled to assign, transfer, charge or in
any way make over the benefit and/or the burden of this Agreement without the
prior written consent of the other which consent shall not be unreasonably
withheld or delayed, save that LB shall be entitled without the prior written
consent of the Customer to assign, transfer, charge, subcontract, deal with or
in any other manner make over the benefit and/or burden of this Agreement to an
or to any company with which LB may merge or to any company to which that LB may
transfer its assets and undertakings.

          12.2 The text of any press release or other communication to be
published by or in the media concerning the subject matter of the Agreement
shall require the prior written approval of LB and the Customer.

          12.3 The Agreement embodies the entire understanding of LB and the
Customer and there are no promises, terms, conditions or obligations, oral or
written, expressed on implied, other than those contained in the Agreement. The
terms of the Agreement shall supersede all previous agreements (if any) which
may exist or have existed between LB and the Customer relating to the Services.

          12.4 The parties to this Agreement do not intend that any term hereof
should be enforceable by virtue of *** by any person who is not a party to this
Agreement.

          12.5 No variation of or addition to this Agreement or any part thereof
shall be effective unless in writing and signed on behalf of both parties.
Notwithstanding the above the parties hereby confirm that amendments to the
Specification shall be effective if reduced to writing and signed by the quality
and/or regulatory representative of both parties, which quality and/or
regulatory representative shall be nominated from time to time by each party.

                                      -11-

<PAGE>

     AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.

Signed for and on behalf of
LONZA BIOLOGICS ***                     ***
                                        ----------------------------------------

                                        ***
                                        ----------------------------------------
                                                                           TITLE

Signed for and on behalf of
GENECRAFT INC.,                         /s/ Peter Thompson
                                        ----------------------------------------
                                        President & CEO                    TITLE

<PAGE>

                                   SCHEDULE 1
                         DEFINITIONS AND SPECIFICATIONS

1.1  DEFINITIONS

     For the purpose of this document:-

     "Cell Line" shall mean any of the *** cell lines supplied by the Customer
expressing Product.

     "Product" shall mean the Small Modular ImmunoPharmaceutical (SMIP) produced
by the Cell Line known as ***.

1.2  CELL LINE ACCEPTANCE CRITERIA

     In order for the Cell Lines to be accepted into LB's development facility,
the following testing is required and the appropriate specifications achieved.

<TABLE>
<CAPTION>
TEST   METHOD   SPECIFICATION
----   ------   -------------
<S>    <C>      <C>
 ***     ***         ***

 ***     ***         ***
</TABLE>

<PAGE>

                                   SCHEDULE 2
                                    SERVICES

2.1  SERVICES

     SUPPLY OF CUSTOMER MATERIALS AND CUSTOMER KNOW-HOW

     Prior to commencement of the Services at LB the Customer shall supply LB
     with the following:

     -    ***

2.2  ACTIVITIES TO BE UNDERTAKEN BY LB

Stage 1   ***

                                      -2-

<PAGE>

                                   SCHEDULE 2
                                    SERVICES

STAGE 1   ***

     1.1  Objectives

          ***

     1.2  Activities

          ***

                                   SCHEDULE 2
                                    SERVICES

          ***

     1.3  DELIVERABLES

          ***

     1.4  TIMESCALE

     Stage 1 shall commence as soon as the Cell Lines are received by LB and
when Biological Safety Committee approval has been obtained. Stage 1 will be
complete upon issue of summary report.

     It is estimated that Stage 1 will take *** to complete.

                                      -3-

<PAGE>

                                   SCHEDULE 3
                           PRICE AND TERMS OF PAYMENT

1.0  PRICE

     In consideration for LB carrying out the Services as detailed in Schedule
2, the Customer shall pay LB as follows:

<TABLE>
<CAPTION>
                        PRICE
 STAGE    DESCRIPTION    ***
-------   -----------   -----
<S>       <C>           <C>
Stage 1       ***        ***
</TABLE>

2.0  PAYMENT

     Payment by the Customer of the Price for each Stage shall be made against
LB's invoices that will be issued as follows:

2.1  For Stage 1

     *** upon commencement of Stage 1.

     *** upon issue of all the deliverables for Stage 1 to the Customer as set
     forth in Section 1.3 of Schedule 2.

                                      -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]